Again because your assumptions are invalid, I do not want to take the time out to go through every point.
You state that the company will receive 100 million in other posts for Sawston, and recall this was all supposed to happen as of the ASM supposedly, but you state they will receive $100 million and then CRL will spend at least an additional $100 million (at a commercial rate), at least, to develop their worldwide production of DCVax-L, not to mention Direct which you reference but NWBO and Cognate already have a contract for trial production for Direct, and it comes with expenses, not revenue.
I just think you seem to understand the relationship as something Cognate wants to pay NWBO for, and that the unfinished facility is worth 50-100 million. If we go back over your past posts, and you do seem to be revising your ideas as we go along, I simply do not believe it is worthwhile to spend a lot of time teasing out and explaining where it gaps from reality.
The company’s current plan, as it has been suggested, is a more coherent, staged and organic plan that hues closer to the appropriate levels that would allow for appropriate scale up and that would be reasonable. In other words, their current plan is manageable and hues to reality. If and when the business requires, I expect at the right time they can get debt financing with the plant, as they need it and far less costly than selling a core and necessary asset as Sawston for developing Flaskworks.
News 
Market Data 
Discover 
